1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Xeroderma Pigmentosum, Complementation Group F: new trials by email Literature Review of Xeroderma Pigmentosum, Complementation Group F trials Research Report on Xeroderma Pigmentosum, Complementation Group F
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE) ARTEGENE drug product - Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 7 | 2023-07-19 | 2026-03-27 |
Severe Combined Immunodeficiency (1) · Severe combined immunodeficiency with sensitivity to ionizing radiation (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · DNA Repair-Deficiency Disorders (1) · Genetic Diseases, Inborn (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Infant, Newborn, Diseases (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1) · Primary Immunodeficiency Diseases (1)
Assistance Publique - Hôpitaux de Paris (1)
France (1)
Chantal Lagresle-Peyrou, MD (1)
2019 (1)